Ablation Devices Market value to hit $25 billion by 2025: Global Market Insights, Inc.
24 juin 2019 06h00 HE
|
Global Market Insights, Inc
Selbyville, Delaware, June 24, 2019 (GLOBE NEWSWIRE) -- The U.S. ablation devices market is the largest in the world and projected to expand at a CAGR of 10.5% over the forecast period. During the...
Ablation Devices Market value to hit $25 billion by 2025: Global Market Insights, Inc.
24 juin 2019 06h00 HE
|
Global Market Insights, Inc
Selbyville, Delaware, June 24, 2019 (GLOBE NEWSWIRE) -- The U.S. ablation devices market is the largest in the world and projected to expand at a CAGR of 10.5% over the forecast period. During the...
First Successful Treatment of Canine Sarcoma using IsoPet® to be Presented at Veterinary Cancer Society Conference
26 sept. 2018 07h00 HE
|
Vivos Inc.
Richland, WA, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC PINK: RDGL) first therapy to canine treat soft tissue sarcoma is successful Vivos Inc, a pharmaceutical company in the process of...
Vivos Inc Retains Well-Known Analyst, George Sharp, as Advisor - Updated
25 sept. 2018 11h12 HE
|
Vivos Inc.
Richland, WA, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Vivos Inc. (OTC: RDGL), a pharmaceutical company in the process of researching and developing minimally invasive treatments to combat cancer in...
Vivos Inc Signs a Standstill Agreement with Debt Holders Designed to Halt the Toxic Selling and Eliminate the Secured Toxic Debt
24 sept. 2018 07h00 HE
|
Vivos Inc.
Richland WA , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Vivos, Inc. (OTC PINK: RDGL) Vivos Inc is pleased to announce that all the debtholders of Vivos’ secured convertible debt have agreed to a ten...
Vivos Inc Signs a Standstill Agreement with Debt Holders Designed to Halt the Toxic Selling and Create a Debt Free Company
21 sept. 2018 17h08 HE
|
Vivos Inc.
Richland WA, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Vivos, Inc. (OTC PINK: RDGL) Vivos Inc is pleased to announce that all the debtholders of Vivos convertible debt have agreed to a 10 day standstill,...
Vivos Inc Successfully Treats Canine Sarcoma with IsoPet™ (RadioGel™)
31 mai 2018 06h00 HE
|
Vivos Inc.
Richland, WA, May 31, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) successfully treated canine soft tissue sarcoma with its proprietary IsoPet™ (RadioGel™), a hydrogel liquid containing tiny...
Vivos Demonstrates that IsoPet™ (RadioGel™) is effective in killing cancer in cats
01 mai 2018 09h00 HE
|
Vivos Inc.
Richland, WA, May 01, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) announced today the results from the therapy for feline sarcoma. Five cats were treated at Washington...
Vivos Adds Commercial Expertise to its Veterinary Medicine Advisory Board
20 mars 2018 09h30 HE
|
Vivos Inc.
Richland, WA, March 20, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) announced today that it added a new member on the Veterinary Medicine Advisory Board. Tariq Shah BSc. DipMS is the...
Vivos Receives FDA Confirmation of RadioGel Device Classification for Animal Skin Cancer Therapy
30 janv. 2018 09h00 HE
|
Vivos Inc.
Richland, WA, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) announced today that it has been notified by the FDA that RadioGel™ is classified as a device for animal therapy. ...